A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...

Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and latent forms of myostatin in order to inhibit myostatin activation.

Conversations with over a dozen college students across the US revealed fears of developing an over-reliance on AI.

The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.

A new study found that highly educated people may suffer steeper cognitive decline after a stroke compared to those with less ...

The realm of outer space has long fascinated humanity, but it also holds significant challenges, especially concerning human health. Recently, the return of two astronauts who spent nine months in ...

When someone has a stroke, it can accelerate the loss of cognitive ability over the coming years. Stroke survivors who have ...

Roche had appealed against a single judge order of March 24 that had refused to stop Natco Pharma from manufacturing a generic version of Risdiplam ...

The Supreme Court is reviewing the legality of the Universal Service Fund (UYF), used to fund phone and internet services in ...

Brain atrophy occurs over time regardless of education level. Our findings suggest that attending higher education may enable people to retain greater cognitive ability until a critical threshold of ...

Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.